Dupilumab Approved by EMA for COPD Treatment in Europe

On July 3rd, 2024, Sanofi and Regeneron jointly announced that their co-developed drug, dupilumab (brand name: Dupixent), has successfully gone through the approval process of the European Medicines Agency (EMA) and been authorized for the treatment of adult patients with COPD (Chronic Obstructive Pulmonary Disease) who have a high blood eosinophil count and whose disease is not adequately controlled with inhaled corticosteroids (ICS), long-acting beta2-agonists (LABA), and long-acting muscarinic antagonists (LAMA) triple therapy, or with LABA and LAMA dual therapy when ICS is not suitable.

This broad approval marks a significant breakthrough in COPD treatment in the European Union, as Dupixent is the first targeted therapy approved for COPD patients. COPD is a highly prevalent chronic respiratory disease characterized by airflow limitation and lung inflammation, which significantly impacts patients' quality of life. Despite the availability of various treatment options, COPD patients still face the challenges of recurrent acute exacerbations and high healthcare costs.

Dupilumab, a fully human monoclonal antibody, works by specifically blocking the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13), reducing the inflammatory response and alleviating COPD symptoms. These two cytokines play a crucial role in the pathogenesis of COPD, and their overexpression leads to worsening lung inflammation and function decline.

It is worth noting that during the approval process with the U.S. Food and Drug Administration (FDA), the agency requested a deeper analysis of the efficacy data from the Phase III BOREAS and NOTUS studies. As a result, the PDUFA (Prescription Drug User Fee Act) date for Dupixent in the U.S. has been delayed from the original June 27th, 2024, to September 27th, 2024. However, Sanofi and Regeneron have proactively responded by submitting the additional data required by the FDA in early May, hoping to expedite the approval in the United States.

The approval of Dupixent in Europe provides a new treatment option for COPD patients, offering the potential for more targeted and effective management of their condition and improved quality of life.